⌘K
t
On 27 February 2026, EDX Medical Group PLC announced its total voting rights. The company has 411,594,583 ordinary shares of 1 pence each in issue, with each share carrying the right to one vote. This figure is for shareholders to determine their notification requirements under the Financial Conduct Authority's Disclosure and Transparency Rules.
| Date | 27 Feb 2026 |
| Time | 14:55:16 |
| Category | Miscellaneous |
| ID | 7766U |
27 February 2026
AQSE: EDX
("EDX Medical" or the "Company")
Total Voting Rights
CAMBRIDGE, UK: EDX Medical Group, plc ("EDX Medical", the "Company" or the "Group"), which develops innovative digital diagnostic products and services for the personalised treatment for cancer, heart disease and infectious diseases, today announces that, in accordance with the Financial Conduct Authority's Disclosure and Transparency Rules, it has 411,594,583 ordinary shares of 1 pence each ("Ordinary Shares") in issue, each share carrying the right to one vote.
The above figure of 411,594,583 Ordinary Shares may be used by shareholders in the Company as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the share capital of the Company under the Financial Conduct Authority's Disclosure and Transparency Rules.
The directors of the Company accept responsibility for the contents of this announcement.
ENDS
Contacts:
|
EDX Medical Group plc |
|
|
Dr Mike Hudson (Chief Executive Officer)
|
+44 (0)7812 345 301
|
|
Oberon Capital |
|
|
Nick Lovering (Corporate Adviser) Adam Pollock (Corporate Broking) Mike Seabrook (Corporate Broking)
|
+44 (0)20 3179 5300 |
|
Media House International |
|
|
Ramsay Smith
Gary McQueen |
+44 (0)7788 414856
+44 (0)7834 694609
|
|
IFC Advisory (Investor Relations) |
|
|
Tim Metcalfe Graham Herring |
+44 (0) 203 934 6630 |
Notes to Editors:
About EDX Medical Group plc
The EDX Medical Group plc is listed on the Apex Segment of the AQSE Growth Market (TIDM: EDX).
EDX Medical was founded by Professor Sir Christopher Evans, OBE, a medical and life sciences entrepreneur with more than 30 years of experience, together with CEO, Dr Mike Hudson.
By translating clinical insights into pragmatic solutions combining advanced biological and digital technologies, EDX Medical seeks to cost effectively improve the detection and characterisation of disease to personalise treatment in a timely fashion. Early disease detection and biologically based personal treatment optimisation is considered to be the most impactful way of improving patient outcomes, reducing deaths and lowering the cost of healthcare globally.
EDX Medical Group provides doctors, hospitals and insurers/payers with access to a portfolio of the best clinical diagnostics products and services. The Company operates its own facilities in Cambridge and Oxford, UK, and has strategic product and technology partnerships with organisations such as Thermo Fisher EMEA Ltd, a world leader in supplying life sciences solutions and services.